Additional Study Information: The abicipar is an injectable medication stored as a liquid in a single-use glass vial for delivery into the back of the eye. The active component is a protein drug that was made using bioengineering technology. It was designed to bind to and inactivate a protein called Vascular Endothelial GrowthFactor (VEGF) that plays an important role in causing AMD. This mechanism of action (anti-VEGF) is similar to some drugs that are currently marketed to treat AMD, including ranibizumab (Lucentis), aflibercept (Eyelea) and pegaptanib (Macugen). Abicipar, like these other drugs, is injected into the eye after careful preparation using a small needle; this is called an intravitrealinjection. The medication halts the formation of new leaky vessels caused by the wet form of agerelatedmacular degeneration and/or strengthens the walls of the existing abnormal blood vessels. Once this happens, the swelling of the retina subsides and the vision improves.